ASA Monitor December 2023, Vol. 87, 18.
Sedative with improved impact on cognitive function presented at SNACC
Eagle Pharmaceuticals, Inc. was chosen for a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care Annual Meeting focusing on their sedative, remimazolam, and its potential impact on cognitive function during procedural sedation.
Remimazolam is a novel benzodiazepine approved by the U.S. Food and Drug Administration (FDA) in July 2020 for sedation in procedures lasting fewer than 30 minutes. The company will share data suggesting that it may have less pronounced effects on cognitive function compared with midazolam when used in conjunction with fentanyl for procedural sedation. Additionally, a unique billing code for remimazolam was established by the Centers for Medicare & Medicaid Services (CMS), effective from July 1, 2023.